Funding sources: this work was supported by a project grant from the Pachyonychia Congenita Project (to F.J.D.S.). The Centre for Dermatology and Genetic Medicine, University of Dundee, is supported by a Wellcome Trust Strategic Award (098439/Z/12/Z to W.H.I.M.).
Resolution of the plantar hyperkeratosis of pachyonychia congenita during chemotherapy for Ewing sarcoma
Version of Record online: 2 DEC 2013
© 2013 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
British Journal of Dermatology
Volume 169, Issue 6, pages 1357–1360, December 2013
How to Cite
Higgins, E., Capra, M., Schwartz, M.E., Smith, F.J.D., McLean, W.H.I. and Irvine, A.D. (2013), Resolution of the plantar hyperkeratosis of pachyonychia congenita during chemotherapy for Ewing sarcoma. British Journal of Dermatology, 169: 1357–1360. doi: 10.1111/bjd.12574
Conflicts of interest: none declared.
- Issue online: 2 DEC 2013
- Version of Record online: 2 DEC 2013
- Accepted manuscript online: 8 AUG 2013 07:57AM EST
- Pachyonychia Congenita Project
- Wellcome Trust Strategic Award. Grant Number: 098439/Z/12/Z
- 1Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumours in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47:22–29., , et al.